DexCom, Inc. (NASDAQ:DXCM) EVP Sadie Stern Sells 1,466 Shares

Key Points

• Sadie Stern, Executive Vice President of DexCom, sold 1,466 shares at an average price of $88.99, totaling approximately $130,459, reducing her ownership by 1.36% to 106,689 shares.
• DexCom reported $0.32 earnings per share for Q1, falling short of analysts' expectations of $0.33, but showed a 12.5% increase in revenue year-over-year.
• Institutional investors now own 97.75% of DexCom’s stock, with notable increases in holdings from firms like Golden State Wealth Management and Stonebridge Financial Group during the first quarter.

DexCom, Inc. (NASDAQ:DXCM - Get Free Report) EVP Sadie Stern sold 1,466 shares of the business's stock in a transaction on Monday, July 28th. The shares were sold at an average price of $88.99, for a total value of $130,459.34. Following the completion of the sale, the executive vice president owned 106,689 shares in the company, valued at $9,494,254.11. This represents a 1.36% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Sadie Stern also recently made the following trade(s):

• On Thursday, June 26th, Sadie Stern sold 1,466 shares of DexCom stock. The shares were sold at an average price of $85.06, for a total value of $124,697.96.
• On Tuesday, May 27th, Sadie Stern sold 6,184 shares of DexCom stock. The stock was sold at an average price of $85.11, for a total transaction of $526,320.24.

DexCom Trading Down 0.2%

DXCM traded down $0.18 during midday trading on Tuesday, reaching $89.35. 2,472,226 shares of the company were exchanged, compared to its average volume of 3,836,732. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.32 and a current ratio of 1.50. DexCom, Inc. has a one year low of $57.52 and a one year high of $93.25. The stock's 50-day simple moving average is $84.63 and its 200 day simple moving average is $80.50. The stock has a market capitalization of $35.04 billion, a P/E ratio of 66.68, a PEG ratio of 1.90 and a beta of 1.44.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). DexCom had a net margin of 12.90% and a return on equity of 30.05%. The firm had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.02 billion. During the same period in the prior year, the business posted $0.32 EPS. The firm's quarterly revenue was up 12.5% compared to the same quarter last year. As a group, analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Institutional Trading of DexCom

A number of institutional investors have recently modified their holdings of DXCM. Golden State Wealth Management LLC increased its position in DexCom by 211.2% in the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock valued at $27,000 after acquiring an additional 264 shares during the period. Private Trust Co. NA boosted its stake in shares of DexCom by 99.4% in the 1st quarter. Private Trust Co. NA now owns 672 shares of the medical device company's stock worth $46,000 after buying an additional 335 shares during the last quarter. Farther Finance Advisors LLC raised its position in DexCom by 29.3% in the first quarter. Farther Finance Advisors LLC now owns 3,100 shares of the medical device company's stock worth $209,000 after acquiring an additional 702 shares during the period. Dynamic Advisor Solutions LLC grew its stake in shares of DexCom by 34.2% during the 1st quarter. Dynamic Advisor Solutions LLC now owns 5,235 shares of the medical device company's stock worth $357,000 after acquiring an additional 1,333 shares during the period. Finally, Stonebridge Financial Group LLC raised its holdings in DexCom by 944.5% during the 1st quarter. Stonebridge Financial Group LLC now owns 3,217 shares of the medical device company's stock valued at $220,000 after acquiring an additional 2,909 shares during the period. 97.75% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have weighed in on DXCM. Mizuho upped their price target on DexCom from $95.00 to $100.00 and gave the stock an "outperform" rating in a report on Wednesday, July 16th. The Goldman Sachs Group initiated coverage on shares of DexCom in a research note on Friday, May 30th. They issued a "buy" rating and a $104.00 price objective on the stock. Wall Street Zen raised DexCom from a "hold" rating to a "buy" rating in a research note on Friday, July 18th. Truist Financial initiated coverage on shares of DexCom in a research report on Monday, June 16th. They set a "buy" rating and a $102.00 target price for the company. Finally, Barclays raised their price target on shares of DexCom from $90.00 to $93.00 and gave the stock an "equal weight" rating in a research note on Monday, May 5th. Four research analysts have rated the stock with a hold rating, fifteen have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $98.72.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.